Global Neurology Clinical Trials Market Overview
Neurology Clinical Trials Market size is projected to reach xxxx units by 2025 from an estimated xxxx unit in 2019, growing at a CAGR of xx% globally.Introspective Market Research provides the newest industry data about Neurology Clinical Trials Market and industry future trends, allowing you to identify the products and end users driving revenue growth and profitability. The Neurology Clinical Trials industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.
Scope of the Neurology Clinical Trials Market
The main goal of this report is to help users understand the Neurology Clinical Trials market in terms of its definition, segmentation, market potential, influential trends, and challenges facing the market. In-depth research and analysis took place while preparing the report. Readers will find this report very helpful to in-depth understanding of the market.Market Segmentation
Players Covered in Neurology Clinical Trials market are :
- Novartis
- Covance
- Medpace
- Charles River Laboratories
- Syneous Health
- Icon Plc
- GlaxoSmithKline
- Aurora healthcare
- Biogen
- IQVIA
| Neurology Clinical Trials Market - Current Analysis by Market Share | |||
|---|---|---|---|
| Segmentations | by Type |
| |
| by Application |
| ||
| by Region |
| ||
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
3.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 4: Neurology Clinical Trials Market by Type
4.1 Neurology Clinical Trials Market Overview Snapshot and Growth Engine
4.2 Neurology Clinical Trials Market Overview
4.3 Phase I
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size (2016-2028F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Phase I: Grographic Segmentation
4.4 Phase II
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size (2016-2028F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Phase II: Grographic Segmentation
4.5 Phase III
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size (2016-2028F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Phase III: Grographic Segmentation
4.6 Phase IV
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size (2016-2028F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Phase IV: Grographic Segmentation
Chapter 5: Neurology Clinical Trials Market by Application
5.1 Neurology Clinical Trials Market Overview Snapshot and Growth Engine
5.2 Neurology Clinical Trials Market Overview
5.3 nterventional
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 nterventional: Grographic Segmentation
5.4 Observational
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Observational: Grographic Segmentation
5.5 Expanded Access
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Expanded Access: Grographic Segmentation
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Positioning
6.1.2 Neurology Clinical Trials Sales and Market Share By Players
6.1.3 Industry BCG Matrix
6.1.4 Ansoff Matrix
6.1.5 Neurology Clinical Trials Industry Concentration Ratio (CR5 and HHI)
6.1.6 Top 5 Neurology Clinical Trials Players Market Share
6.1.7 Mergers and Acquisitions
6.1.8 Business Strategies By Top Players
6.2 NOVARTIS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.2.8 SWOT Analysis
6.3 COVANCE
6.4 MEDPACE
6.5 CHARLES RIVER LABORATORIES
6.6 SYNEOUS HEALTH
6.7 ICON PLC
6.8 GLAXOSMITHKLINE
6.9 AURORA HEALTHCARE
6.10 BIOGEN
6.11 IQVIA
Chapter 7: Global Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
7.1 Market Overview
7.2 Historic and Forecasted Market Size By Type
7.2.1 Phase I
7.2.2 Phase II
7.2.3 Phase III
7.2.4 Phase IV
7.3 Historic and Forecasted Market Size By Application
7.3.1 nterventional
7.3.2 Observational
7.3.3 Expanded Access
Chapter 8: North America Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
8.1 Key Market Trends, Growth Factors and Opportunities
8.2 Impact of Covid-19
8.3 Key Players
8.4 Key Market Trends, Growth Factors and Opportunities
8.4 Historic and Forecasted Market Size By Type
8.4.1 Phase I
8.4.2 Phase II
8.4.3 Phase III
8.4.4 Phase IV
8.5 Historic and Forecasted Market Size By Application
8.5.1 nterventional
8.5.2 Observational
8.5.3 Expanded Access
8.6 Historic and Forecast Market Size by Country
8.6.1 U.S.
8.6.2 Canada
8.6.3 Mexico
Chapter 9: Europe Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Phase I
9.4.2 Phase II
9.4.3 Phase III
9.4.4 Phase IV
9.5 Historic and Forecasted Market Size By Application
9.5.1 nterventional
9.5.2 Observational
9.5.3 Expanded Access
9.6 Historic and Forecast Market Size by Country
9.6.1 Germany
9.6.2 U.K.
9.6.3 France
9.6.4 Italy
9.6.5 Russia
9.6.6 Spain
Chapter 10: Asia-Pacific Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Phase I
10.4.2 Phase II
10.4.3 Phase III
10.4.4 Phase IV
10.5 Historic and Forecasted Market Size By Application
10.5.1 nterventional
10.5.2 Observational
10.5.3 Expanded Access
10.6 Historic and Forecast Market Size by Country
10.6.1 China
10.6.2 India
10.6.3 Japan
10.6.4 Southeast Asia
Chapter 11: South America Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Phase I
11.4.2 Phase II
11.4.3 Phase III
11.4.4 Phase IV
11.5 Historic and Forecasted Market Size By Application
11.5.1 nterventional
11.5.2 Observational
11.5.3 Expanded Access
11.6 Historic and Forecast Market Size by Country
11.6.1 Brazil
11.6.2 Argentina
Chapter 12: Middle East & Africa Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Phase I
12.4.2 Phase II
12.4.3 Phase III
12.4.4 Phase IV
12.5 Historic and Forecasted Market Size By Application
12.5.1 nterventional
12.5.2 Observational
12.5.3 Expanded Access
12.6 Historic and Forecast Market Size by Country
12.6.1 Saudi Arabia
12.6.2 South Africa
Chapter 13 Investment Analysis
Chapter 14 Analyst Viewpoint and Conclusion
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
3.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 4: Neurology Clinical Trials Market by Type
4.1 Neurology Clinical Trials Market Overview Snapshot and Growth Engine
4.2 Neurology Clinical Trials Market Overview
4.3 Phase I
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size (2016-2028F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Phase I: Grographic Segmentation
4.4 Phase II
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size (2016-2028F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Phase II: Grographic Segmentation
4.5 Phase III
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size (2016-2028F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Phase III: Grographic Segmentation
4.6 Phase IV
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size (2016-2028F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Phase IV: Grographic Segmentation
Chapter 5: Neurology Clinical Trials Market by Application
5.1 Neurology Clinical Trials Market Overview Snapshot and Growth Engine
5.2 Neurology Clinical Trials Market Overview
5.3 nterventional
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 nterventional: Grographic Segmentation
5.4 Observational
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Observational: Grographic Segmentation
5.5 Expanded Access
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Expanded Access: Grographic Segmentation
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Positioning
6.1.2 Neurology Clinical Trials Sales and Market Share By Players
6.1.3 Industry BCG Matrix
6.1.4 Ansoff Matrix
6.1.5 Neurology Clinical Trials Industry Concentration Ratio (CR5 and HHI)
6.1.6 Top 5 Neurology Clinical Trials Players Market Share
6.1.7 Mergers and Acquisitions
6.1.8 Business Strategies By Top Players
6.2 NOVARTIS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.2.8 SWOT Analysis
6.3 COVANCE
6.4 MEDPACE
6.5 CHARLES RIVER LABORATORIES
6.6 SYNEOUS HEALTH
6.7 ICON PLC
6.8 GLAXOSMITHKLINE
6.9 AURORA HEALTHCARE
6.10 BIOGEN
6.11 IQVIA
Chapter 7: Global Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
7.1 Market Overview
7.2 Historic and Forecasted Market Size By Type
7.2.1 Phase I
7.2.2 Phase II
7.2.3 Phase III
7.2.4 Phase IV
7.3 Historic and Forecasted Market Size By Application
7.3.1 nterventional
7.3.2 Observational
7.3.3 Expanded Access
Chapter 8: North America Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
8.1 Key Market Trends, Growth Factors and Opportunities
8.2 Impact of Covid-19
8.3 Key Players
8.4 Key Market Trends, Growth Factors and Opportunities
8.4 Historic and Forecasted Market Size By Type
8.4.1 Phase I
8.4.2 Phase II
8.4.3 Phase III
8.4.4 Phase IV
8.5 Historic and Forecasted Market Size By Application
8.5.1 nterventional
8.5.2 Observational
8.5.3 Expanded Access
8.6 Historic and Forecast Market Size by Country
8.6.1 U.S.
8.6.2 Canada
8.6.3 Mexico
Chapter 9: Europe Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Phase I
9.4.2 Phase II
9.4.3 Phase III
9.4.4 Phase IV
9.5 Historic and Forecasted Market Size By Application
9.5.1 nterventional
9.5.2 Observational
9.5.3 Expanded Access
9.6 Historic and Forecast Market Size by Country
9.6.1 Germany
9.6.2 U.K.
9.6.3 France
9.6.4 Italy
9.6.5 Russia
9.6.6 Spain
Chapter 10: Asia-Pacific Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Phase I
10.4.2 Phase II
10.4.3 Phase III
10.4.4 Phase IV
10.5 Historic and Forecasted Market Size By Application
10.5.1 nterventional
10.5.2 Observational
10.5.3 Expanded Access
10.6 Historic and Forecast Market Size by Country
10.6.1 China
10.6.2 India
10.6.3 Japan
10.6.4 Southeast Asia
Chapter 11: South America Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Phase I
11.4.2 Phase II
11.4.3 Phase III
11.4.4 Phase IV
11.5 Historic and Forecasted Market Size By Application
11.5.1 nterventional
11.5.2 Observational
11.5.3 Expanded Access
11.6 Historic and Forecast Market Size by Country
11.6.1 Brazil
11.6.2 Argentina
Chapter 12: Middle East & Africa Neurology Clinical Trials Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Phase I
12.4.2 Phase II
12.4.3 Phase III
12.4.4 Phase IV
12.5 Historic and Forecasted Market Size By Application
12.5.1 nterventional
12.5.2 Observational
12.5.3 Expanded Access
12.6 Historic and Forecast Market Size by Country
12.6.1 Saudi Arabia
12.6.2 South Africa
Chapter 13 Investment Analysis
Chapter 14 Analyst Viewpoint and Conclusion
| Neurology Clinical Trials Market - Current Analysis by Market Share | |||
|---|---|---|---|
| Segmentations | by Type |
| |
| by Application |
| ||
| by Region |
| ||
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. NEUROLOGY CLINICAL TRIALS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. NEUROLOGY CLINICAL TRIALS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. NEUROLOGY CLINICAL TRIALS MARKET COMPETITIVE RIVALRY
TABLE 005. NEUROLOGY CLINICAL TRIALS MARKET THREAT OF NEW ENTRANTS
TABLE 006. NEUROLOGY CLINICAL TRIALS MARKET THREAT OF SUBSTITUTES
TABLE 007. NEUROLOGY CLINICAL TRIALS MARKET BY TYPE
TABLE 008. PHASE I MARKET OVERVIEW (2016-2028)
TABLE 009. PHASE II MARKET OVERVIEW (2016-2028)
TABLE 010. PHASE III MARKET OVERVIEW (2016-2028)
TABLE 011. PHASE IV MARKET OVERVIEW (2016-2028)
TABLE 012. NEUROLOGY CLINICAL TRIALS MARKET BY APPLICATION
TABLE 013. NTERVENTIONAL MARKET OVERVIEW (2016-2028)
TABLE 014. OBSERVATIONAL MARKET OVERVIEW (2016-2028)
TABLE 015. EXPANDED ACCESS MARKET OVERVIEW (2016-2028)
TABLE 016. NORTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 017. NORTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 018. N NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 019. EUROPE NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 020. EUROPE NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 021. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 022. ASIA PACIFIC NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 023. ASIA PACIFIC NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 024. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 026. MIDDLE EAST & AFRICA NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 027. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 028. SOUTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 029. SOUTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 030. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 031. NOVARTIS: SNAPSHOT
TABLE 032. NOVARTIS: BUSINESS PERFORMANCE
TABLE 033. NOVARTIS: PRODUCT PORTFOLIO
TABLE 034. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. COVANCE: SNAPSHOT
TABLE 035. COVANCE: BUSINESS PERFORMANCE
TABLE 036. COVANCE: PRODUCT PORTFOLIO
TABLE 037. COVANCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. MEDPACE: SNAPSHOT
TABLE 038. MEDPACE: BUSINESS PERFORMANCE
TABLE 039. MEDPACE: PRODUCT PORTFOLIO
TABLE 040. MEDPACE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. CHARLES RIVER LABORATORIES: SNAPSHOT
TABLE 041. CHARLES RIVER LABORATORIES: BUSINESS PERFORMANCE
TABLE 042. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 043. CHARLES RIVER LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. SYNEOUS HEALTH: SNAPSHOT
TABLE 044. SYNEOUS HEALTH: BUSINESS PERFORMANCE
TABLE 045. SYNEOUS HEALTH: PRODUCT PORTFOLIO
TABLE 046. SYNEOUS HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. ICON PLC: SNAPSHOT
TABLE 047. ICON PLC: BUSINESS PERFORMANCE
TABLE 048. ICON PLC: PRODUCT PORTFOLIO
TABLE 049. ICON PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. GLAXOSMITHKLINE: SNAPSHOT
TABLE 050. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 051. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 052. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. AURORA HEALTHCARE: SNAPSHOT
TABLE 053. AURORA HEALTHCARE: BUSINESS PERFORMANCE
TABLE 054. AURORA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 055. AURORA HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. BIOGEN: SNAPSHOT
TABLE 056. BIOGEN: BUSINESS PERFORMANCE
TABLE 057. BIOGEN: PRODUCT PORTFOLIO
TABLE 058. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. IQVIA: SNAPSHOT
TABLE 059. IQVIA: BUSINESS PERFORMANCE
TABLE 060. IQVIA: PRODUCT PORTFOLIO
TABLE 061. IQVIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY TYPE
FIGURE 012. PHASE I MARKET OVERVIEW (2016-2028)
FIGURE 013. PHASE II MARKET OVERVIEW (2016-2028)
FIGURE 014. PHASE III MARKET OVERVIEW (2016-2028)
FIGURE 015. PHASE IV MARKET OVERVIEW (2016-2028)
FIGURE 016. NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY APPLICATION
FIGURE 017. NTERVENTIONAL MARKET OVERVIEW (2016-2028)
FIGURE 018. OBSERVATIONAL MARKET OVERVIEW (2016-2028)
FIGURE 019. EXPANDED ACCESS MARKET OVERVIEW (2016-2028)
FIGURE 020. NORTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. EUROPE NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. ASIA PACIFIC NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. MIDDLE EAST & AFRICA NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. SOUTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. NEUROLOGY CLINICAL TRIALS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. NEUROLOGY CLINICAL TRIALS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. NEUROLOGY CLINICAL TRIALS MARKET COMPETITIVE RIVALRY
TABLE 005. NEUROLOGY CLINICAL TRIALS MARKET THREAT OF NEW ENTRANTS
TABLE 006. NEUROLOGY CLINICAL TRIALS MARKET THREAT OF SUBSTITUTES
TABLE 007. NEUROLOGY CLINICAL TRIALS MARKET BY TYPE
TABLE 008. PHASE I MARKET OVERVIEW (2016-2028)
TABLE 009. PHASE II MARKET OVERVIEW (2016-2028)
TABLE 010. PHASE III MARKET OVERVIEW (2016-2028)
TABLE 011. PHASE IV MARKET OVERVIEW (2016-2028)
TABLE 012. NEUROLOGY CLINICAL TRIALS MARKET BY APPLICATION
TABLE 013. NTERVENTIONAL MARKET OVERVIEW (2016-2028)
TABLE 014. OBSERVATIONAL MARKET OVERVIEW (2016-2028)
TABLE 015. EXPANDED ACCESS MARKET OVERVIEW (2016-2028)
TABLE 016. NORTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 017. NORTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 018. N NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 019. EUROPE NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 020. EUROPE NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 021. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 022. ASIA PACIFIC NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 023. ASIA PACIFIC NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 024. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 026. MIDDLE EAST & AFRICA NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 027. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 028. SOUTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY TYPE (2016-2028)
TABLE 029. SOUTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET, BY APPLICATION (2016-2028)
TABLE 030. NEUROLOGY CLINICAL TRIALS MARKET, BY COUNTRY (2016-2028)
TABLE 031. NOVARTIS: SNAPSHOT
TABLE 032. NOVARTIS: BUSINESS PERFORMANCE
TABLE 033. NOVARTIS: PRODUCT PORTFOLIO
TABLE 034. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. COVANCE: SNAPSHOT
TABLE 035. COVANCE: BUSINESS PERFORMANCE
TABLE 036. COVANCE: PRODUCT PORTFOLIO
TABLE 037. COVANCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. MEDPACE: SNAPSHOT
TABLE 038. MEDPACE: BUSINESS PERFORMANCE
TABLE 039. MEDPACE: PRODUCT PORTFOLIO
TABLE 040. MEDPACE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. CHARLES RIVER LABORATORIES: SNAPSHOT
TABLE 041. CHARLES RIVER LABORATORIES: BUSINESS PERFORMANCE
TABLE 042. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 043. CHARLES RIVER LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. SYNEOUS HEALTH: SNAPSHOT
TABLE 044. SYNEOUS HEALTH: BUSINESS PERFORMANCE
TABLE 045. SYNEOUS HEALTH: PRODUCT PORTFOLIO
TABLE 046. SYNEOUS HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. ICON PLC: SNAPSHOT
TABLE 047. ICON PLC: BUSINESS PERFORMANCE
TABLE 048. ICON PLC: PRODUCT PORTFOLIO
TABLE 049. ICON PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. GLAXOSMITHKLINE: SNAPSHOT
TABLE 050. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 051. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 052. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. AURORA HEALTHCARE: SNAPSHOT
TABLE 053. AURORA HEALTHCARE: BUSINESS PERFORMANCE
TABLE 054. AURORA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 055. AURORA HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. BIOGEN: SNAPSHOT
TABLE 056. BIOGEN: BUSINESS PERFORMANCE
TABLE 057. BIOGEN: PRODUCT PORTFOLIO
TABLE 058. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. IQVIA: SNAPSHOT
TABLE 059. IQVIA: BUSINESS PERFORMANCE
TABLE 060. IQVIA: PRODUCT PORTFOLIO
TABLE 061. IQVIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY TYPE
FIGURE 012. PHASE I MARKET OVERVIEW (2016-2028)
FIGURE 013. PHASE II MARKET OVERVIEW (2016-2028)
FIGURE 014. PHASE III MARKET OVERVIEW (2016-2028)
FIGURE 015. PHASE IV MARKET OVERVIEW (2016-2028)
FIGURE 016. NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY APPLICATION
FIGURE 017. NTERVENTIONAL MARKET OVERVIEW (2016-2028)
FIGURE 018. OBSERVATIONAL MARKET OVERVIEW (2016-2028)
FIGURE 019. EXPANDED ACCESS MARKET OVERVIEW (2016-2028)
FIGURE 020. NORTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. EUROPE NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. ASIA PACIFIC NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. MIDDLE EAST & AFRICA NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. SOUTH AMERICA NEUROLOGY CLINICAL TRIALS MARKET OVERVIEW BY COUNTRY (2016-2028)
Frequently Asked Questions :
What would be forecast period in the market research report?
The forecast period in the market research report is 2021-2027.
Who are the key players in Neurology Clinical Trials market?
The key players mentioned are Novartis,Covance,Medpace,Charles River Laboratories,Syneous Health,Icon Plc,GlaxoSmithKline,Aurora healthcare,Biogen,IQVIA.
What are the segments of Neurology Clinical Trials market?
The Neurology Clinical Trials market is segmented into application type, product type and region. By Application type, the market is categorized into nterventional, Observational, Expanded Access. By product type, it is classified into Phase I, Phase II, Phase III, Phase IV and others. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-Pacific (China; India; Japan; Southeast Asia etc.), South America (Brazil; Argentina etc.), Middle East & Africa (Saudi Arabia; South Africa etc.).
What is the Neurology Clinical Trials market?
Neurology Clinical Trials Market size is projected to reach xxxx units by 2027 from an estimated xxxx unit in 2020, growing at a CAGR of xx% globally.
How big is the Neurology Clinical Trials market?
The global Neurology Clinical Trials market size was estimated at USD XX billion in 2020 and is expected to reach USD XX billion in 2027.
